VistaGen Therapeutics, Inc., a biotechnology company, focuses on applying proprietary human pluripotent stem cell technology for technology for drug rescue, predictive toxicology, and drug metabolism screening. The company has developed CardioSafe 3D, a novel three-dimensional in vitro bioassay system for predicting in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in animals or humans. It is also developing and validating LiverSafe 3D, a novel three-dimensional in vitro bioassay system for assessing liver toxicity and drug metabolism issues. In addition, the company product candidates include AV-101, an orally available small molecule that has completed Phase 1 development for the treatment of neurological disease and disorders market, including neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
February 6, 2018
RegMed Investors’ (RMi) closing bell; sector reverses and flip-flops by the hour
February 5, 2018
RegMed Investors’ (RMi) closing bell; be very careful in buying any dips
February 2, 2018
RegMed Investors’ (RMi) closing bell; volatility is raining on share pricing without an umbrella
February 1, 2018
RegMed Investors’ (RMi) closing bell; just when even I thought the selling would abate
January 31, 2018
RegMed Investors’ (RMi) closing bell; peeling the risk “onion” one session at a time
January 30, 2018
RegMed Investors’ (RMi) closing bell; made more, lost some
January 29, 2018
RegMed Investors’ (RMi) closing bell; another week begins volatile
January 26, 2018
RegMed Investors’ (RMi) closing bell; a daily rotation as …
January 24, 2018
RegMed Investors’ (RMi) closing bell; right again…
January 23, 2018
RegMed Investors’ (RMi) closing bell; exuberance is a noun associated with a transformative event
35 companies, 1 interpreter!
Insight, foresight and recommendation
VistaGen (VTGN) – Started 2018 at $1.16, February saw $1.16 and March opened at $1.18 jumping to $1.47 on 3/6. Financing is always an issue yet it ended 2017 with $13 M in cash ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors